@article{4baabe019a084937af9ccf52411e0217,
title = "Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: Successes and barriers",
abstract = "The most significant long-term complication of radiotherapy in the head-and-neck region is hyposalivation and its related complaints, particularily xerostomia. This review addresses the pathophysiology underlying irradiation damage to salivary gland tissue, the consequences of radiation injury, and issues contributing to the clinical management of salivary gland hypofunction and xerostomia. These include ways to (1) prevent or minimize radiation injury of salivary gland tissue, (2) manage radiation-induced hyposalivation and xerostomia, and (3) restore the function of salivary gland tissue damaged by radiotherapy.",
keywords = "Gene transfer, Hyposalivation, Palliative care, Prevention, Radiotherapy, Stem cell therapy, Xerostomia",
author = "Arjan Vissink and Mitchell, {James B.} and Baum, {Bruce J.} and Limesand, {Kirsten H.} and Jensen, {Siri Beier} and Fox, {Philip C.} and Elting, {Linda S.} and Langendijk, {Johannes A.} and Coppes, {Robert P.} and Reyland, {Mary E.}",
note = "Funding Information: Funding for this conference was made possible in part by Award Number R13 DE19330 from the National Institute of Dental and Craniofacial Research . The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Partial funding was also provided by the National Cancer Institute , the National Institutes of Health Office of Rare Diseases , The University of Connecticut School of Dental Medicine , Carolinas Medical Center , The Multinational Association of Supportive Care in Cancer , and the International Society of Oral Oncology . This conference was also supported by unrestricted educational grant funds from Endo Pharmaceuticals, Inc. and from EUSA Pharma , and by funds from Biovitrum and Helsinn Healthcare SA . ",
year = "2010",
month = nov,
day = "4",
doi = "10.1016/j.ijrobp.2010.06.052",
language = "English (US)",
volume = "78",
pages = "983--991",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",
}